Vanda Pharmaceuticals (NASDAQ:VNDA) Stock Rating Raised to “Hold” at Zacks Research

Zacks Research upgraded shares of Vanda Pharmaceuticals (NASDAQ:VNDA) from a strong sell rating to a hold rating in a research report report published on Wednesday morning,Zacks reports.

A number of other analysts have also recently commented on the company. Wall Street Zen upgraded Vanda Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, October 31st. Oppenheimer assumed coverage on Vanda Pharmaceuticals in a research report on Wednesday, September 23rd. They issued an “outperform” rating and a $10.00 target price for the company. HC Wainwright restated a “buy” rating on shares of Vanda Pharmaceuticals in a research note on Monday. B. Riley Financial reaffirmed a “buy” rating and set a $12.00 price target (down from $17.00) on shares of Vanda Pharmaceuticals in a research report on Monday, August 10th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research note on Thursday, October 15th. Six equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $13.50.

Vanda Pharmaceuticals Price Performance

Shares of NASDAQ:VNDA opened at $3.59 on Wednesday. The company’s fifty day moving average price is $4.66 and its 200 day moving average price is $6.14. Vanda Pharmaceuticals has a 12 month low of $3.57 and a 12 month high of $9.94. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.54 and a quick ratio of 1.53. The firm has a market capitalization of $217.09 million, a P/E ratio of -0.78 and a beta of 0.74.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings results on Wednesday, October 28th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.31. Vanda Pharmaceuticals had a negative net margin of 119.87% and a negative return on equity of 62.70%. The firm had revenue of $69.81 million during the quarter, compared to analysts’ expectations of $69.20 million. As a group, sell-side analysts predict that Vanda Pharmaceuticals will post -2.53 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Cornerstone Wealth Management LLC purchased a new stake in shares of Vanda Pharmaceuticals in the third quarter valued at about $83,000. AIGH Capital Management LLC boosted its stake in shares of Vanda Pharmaceuticals by 10.1% during the third quarter. AIGH Capital Management LLC now owns 2,250,000 shares of the biopharmaceutical company’s stock worth $11,048,000 after buying an additional 205,831 shares during the period. State Street Corp grew its holdings in shares of Vanda Pharmaceuticals by 16.6% during the second quarter. State Street Corp now owns 3,516,405 shares of the biopharmaceutical company’s stock worth $21,520,000 after buying an additional 500,843 shares during the last quarter. Syon Capital LLC purchased a new position in shares of Vanda Pharmaceuticals during the second quarter worth about $125,000. Finally, Hsbc Holdings PLC grew its holdings in shares of Vanda Pharmaceuticals by 144.5% during the second quarter. Hsbc Holdings PLC now owns 94,988 shares of the biopharmaceutical company’s stock worth $579,000 after buying an additional 56,133 shares during the last quarter. 88.14% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Vanda Pharmaceuticals

Here are the key news stories impacting Vanda Pharmaceuticals this week:

• Positive Sentiment: Director Charles Cliff Duncan bought a combined 10,000 shares from November 3–5 for approximately $38,069, increasing his ownership. SEC ownership filing
• Neutral Sentiment: HC Wainwright maintained its Buy rating and raised its 2026 EPS estimate to a loss of $2.45 from a loss of $3.03, including a narrower projected Q4 loss.
• Negative Sentiment: HC Wainwright lowered estimates for Q2–Q4 2027 and cut its full-year 2027 EPS forecast to a loss of $1.02 from a loss of $0.94, signaling a less favorable outlook for those periods.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders and other conditions with significant unmet medical needs. Founded in 2003 and headquartered in Washington, DC, the company primarily serves patients and healthcare providers in the United States, with certain products and commercial rights extending to international markets.

Vanda’s marketed products include Hetlioz (tasimelteon), a treatment for Non-24-Hour Sleep-Wake Disorder in totally blind individuals and nighttime sleep disturbances associated with Smith-Magenis syndrome.